注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
ProQR Therapeutics NV是一家位于荷兰的临床前生物制药公司。该公司从事发现和开发基于核糖核酸(RNA)的治疗严重遗传疾病的疗法。它设计其治疗候选物以专门针对和修复有缺陷的信使RNA或信使核糖核酸(mRNA),该信使核糖核酸(mRNA)从突变基因转录而来,以恢复正常或野生型蛋白质的表达和功能。其候选产品包括QR-010,一种用于治疗囊性纤维化(CF)的基于RNA的寡核苷酸,QR-110,一种用于治疗Leber先天性黑蒙(LCA)的寡核苷酸。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Donald S. Fong | - | 2020 | Member of Scientific Advisory Board |
Bart Filius | 51 | 2019 | Independent Supervisory Board Member |
James S. Shannon | 65 | 2016 | Independent Member of Supervisory Board & Chairman of Scientific Advisory Board |
Domenico Valerio | 66 | 2014 | Founder & Independent Chairman of Supervisory Board |
Theresa Marie Heggie | 64 | 2021 | Supervisory Board Member |
Alison F. Lawton | 63 | 2014 | Independent Member of Supervisory Board |
Peter A. Beal | - | 2018 | Member Scientific Advisory Board |
Phillip D. Zamore | - | 2017 | Member of Scientific Advisory Board |
Yi-Tao Yu | - | 2018 | Member of Scientific Advisory Board |
Martin A. Maier | - | 2020 | Member of Scientific Advisory Board |
Begona Carreno | 53 | 2023 | Supervisory Board Member |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核